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• Inhibiting GSTA2 func-
tion in vivo prolongs the
overall survival of AML
mice with intermediate
RUNX1 expressions.
Besides being a classical tumor suppressor, runt-related transcription factor 1 (RUNX1) is
now widely recognized for its oncogenic role in the development of acute myeloid leukemia
(AML). Herewe report that this bidirectional function of RUNX1possibly arises from the total
level of RUNX family expressions. Indeed, analysis of clinical data revealed that intermediate-
level gene expression of RUNX1 marked the poorest-prognostic cohort in relation to AML
patients with high- or low-level RUNX1 expressions. Through a series of RUNX1 knockdown
experiments with various RUNX1 attenuation potentials, we found that moderate
attenuation of RUNX1 contributed to the enhanced propagation of AML cells through
accelerated cell-cycle progression, whereas profound RUNX1 depletion led to cell-cycle
arrest and apoptosis. In these RUNX1-silenced tumors, amounts of compensative
upregulation of RUNX2 and RUNX3 expressions were roughly equivalent and created an
absolute elevation of total RUNX (RUNX1 1 RUNX2 1 RUNX3) expression levels in RUNX1
moderately attenuated AML cells. This elevation resulted in enhanced transactivation
of glutathione S-transferase a 2 (GSTA2) expression, a vital enzyme handling the
catabolization of intracellular reactive oxygen species (ROS) as well as advancing the
cell-cycle progressions, and thus ultimately led to the acquisition of proliferative advantage
in RUNX1 moderately attenuated AML cells. Besides, treatment with ethacrynic acid, which
is known for its GSTA inhibiting property, actually prolonged the survival of AML mice in
vivo. Collectively, our ﬁndings indicate that moderately attenuated RUNX1 expressions
paradoxically enhance leukemogenesis in AML cells through intracellular environmental
change via GSTA2, which could be a novel therapeutic target in antileukemia strategy.
Introduction
RUNX1, a member of RUNX transcription family proteins (RUNX1, RUNX2, and RUNX3), is an essential
transcription factor mediating diverse functions in mammalian cells including cell differentiation,
proliferation, cell-cycle regulation, and apoptosis. RUNX1 forms a stable heterodimeric complex with
core-binding factor beta on the genome DNA sequence specifically and enhances the transcription of
the target genes. Frequent gene alterations including mutations and translocations in RUNX1 provided
the basis for classical conception that regards RUNX1 as an oncosuppressor.1,2 This classical viewpoint
has been challenged by our recent findings that wild-type RUNX1 is stringently required for the
development of acute myeloid leukemia (AML) with inv(16) or with mixed-lineage leukemia (MLL)
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fusions.3-5 We have also discovered the requirement of RUNX
family proteins in the maintenance of leukemia cells as well as of
tumors derived from various origins and first shed light on the
oncogenic property of RUNX family proteins in the initiation and
maintenance of malignant tumors in general.6 Although we have
revealed the functional redundancy of RUNX family members in
leukemogenesis and the significance of total amount of RUNX family
(RUNX1 1 RUNX2 1 RUNX3) expressions in the maintenance of
AML cells in the previous report, the impact of RUNX1 expression
levels on the total amount of RUNX expressions or the precise
mechanism of RUNX1-derived tumorigenesis remains elusive.6
Glutathione S-transferase (GST) is a cytosolic and membrane-
bound enzyme handling the detoxification of electrophilic com-
pounds such as chemotherapeutic drugs, environmental toxins, and
products of oxidative stress, through conjugating with glutathione.
At present, 8 distinct classes of the soluble cytoplasmic mammalian
glutathione S-transferases have been identified, and the a subtype
(GSTA) is the most abundant form among them.7 In addition to
metabolizing bilirubin and certain anticancer drugs in the liver,
GSTA is reported to exhibit glutathione peroxidase activity, thereby
protecting the cells from ROS and the products of peroxidation. The
accumulating intracellular ROS leads to transient cell-cycle arrest
and protects genome DNAs from unnecessary oxidative injury
from ROS.8 GSTA is therefore considered to function as a pro-
oncogenic enzyme through down-regulating intracellular ROS
levels and advancing cell- cycle progressions.9,10 Despite these
findings, little has been known about the interaction between RUNX
family genes and GST or ROS.
We herein address the impact of the varying levels of RUNX1
expressions on the total amount of RUNX expressions and on the
propagation of AML cells as well as on the clinical outcomes and
investigate the novel leukemogenic RUNX-GST-ROS axis.
Methods
Cell lines
AML-derived MV4-11 cells were purchased from American Type
Culture Collection. AML-derived OCI-AML2, OCI-AML3, and
MOLM-13 cells were purchased from Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH (Germany). These AML
cell lines were maintained in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal bovine serum (FBS) and 1%
penicillin-streptomycin (PS). HEK293T cells were purchased from
RIKEN BioResource Center (BRC; Japan) and maintained in
Dulbecco’s modified Eagle’s medium with 10% FBS and 1% PS.
Cells were cultured at 37°C, 5% CO2.
Cell proliferation
To assess cell proliferation, we seeded 1 3 105 cells of the
indicated AML-derived cells in a 6-well plate. For the tetracycline
inducible gene or short hairpin RNA (shRNA) expressions,
doxycycline was added to the culture at a final concentration of
3 mM. Trypan blue dye exclusion assays were performed every
other day.
qRT-PCR
Total RNA was isolated with RNeasy Mini Kit (Qiagen) and reverse-
transcribed with Reverse Script Kit (TOYOBO) to generate
complementary DNA (cDNA). Quantitative real-time polymerase
chain reaction (qRT-PCR) was carried out with 7500 Real-time
Polymerase Chain Reaction (PCR) System (Applied Biosystems)
according to the manufacturer’s instructions. The results were
normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
levels. Relative expression levels were calculated using the 2-DDCt
method. Primers used for qRT-PCR were listed in supplemental
Table 1.
ChIP-qPCR
Chromatin immunoprecipitation assay (ChIP) was performed by
using SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling
Technology) according to the manufacturer’s instructions. In brief,
cells were cross-linked in 1% formaldehyde in phosphate-buffered
saline (PBS) for 10 min at room temperature. After glycine
quenching, cell pellets were collected, lysed, and then subjected
to sonication with Q55 sonicator system (QSONICA). The
supernatant was diluted with the same sonication buffer and
processed for immunoprecipitation with the following antibodies
at 4°C overnight: anti-RUNX1 antibody (ab23980; Abcam), anti-
RUNX2 antibody (D1L7F; Cell Signaling Technology), and anti-
RUNX3 antibody (ab11905; Abcam). The beads were then
washed and DNA was reverse cross-linked and purified. Follow-
ing ChIP, DNA was quantified by qPCR using the standard
procedures for 7500 Real-Time PCR System (Applied Biosys-
tems). Primers used for ChIP-qPCR are listed in supplemental
Table 2.
siRNA interference
Specific shRNAs targeting human RUNX1 and GSTA2 were
designed and subcloned into pENTR4-H1tetOx1, CS-RfA-ETV,
and CS-RfA-ETR vectors (RIKEN BRC). Nontargeting control
shRNA was designed against luciferase (sh_Luc.). The target
sequences are provided in supplemental Table 3.
Expression plasmids
We have amplified cDNAs for human RUNX1, RUNX2, RUNX3,
and GSTA2 and then inserted them into CSII-EF-MCS-IRES2-
Venus, CSII-EF-MCS-IRES2-hKO1, and CSIV-TRE-Ubc-KT ex-
pression vectors. All of the PCR products were verified by DNA
sequencing.
Production and transduction of lentivirus
For the production of lentivirus, HEK293T cells were transiently
cotransfected with lentivirus vectors such as psPAX2 and pMD2.G
by polyethylenimine (PEI, Sigma-Aldrich). Forty-eight hours after
transfection, viral supernatants were collected and immediately used
for infection, and then successfully transduced cells were sorted by
flow cytometer Aria III (BD Biosciences).
Immunoblotting
Immunoblotting was conducted as has been previously de-
scribed.11 Briefly, cells were washed twice in ice-cold PBS and
lysed in lysis buffer (50 mM Tris [pH 7.4], 100 mM NaCl, 0.1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM b-glycerophos-
phate, 2.5 mM sodium pyrophosphate, 1mM Na3VO4, 13 protease
inhibitor [Roche], and PhosSTOP [Roche]). Whole-cell extracts
were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis and electrotransferred onto polyvinylidene difluor-
ide membranes. Membranes were probed with the following primary
antibodies: anti-RUNX1 (A-2, Santa Cruz Biotechnology, Inc.),
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anti-GAPDH (FL-335, Santa Cruz Biotechnology, Inc.), anti-RUNX2
(D1L7F, Cell Signaling Technology), anti-RUNX3 (D6E2, Cell
Signaling Technology), and anti-GSTA2 (NBP1-32157, Novus
Biologicals, LLC) antibodies. For secondary antibodies, horseradish
peroxidase-conjugated anti-rabbit immunoglobulin G (IgG) and anti-
mouse IgG (Cell Signaling Technology) were used. Blots were
visualized using Chemi-Lumi One Super (nacalai tesque, Inc.) and
ChemiDoc XRS1 Imager (Bio-Rad Laboratories, Inc.), according to
the manufacturers’ recommendations. Protein levels were quanti-





















































   
   






























































































































































Figure 1. Moderate inhibition of RUNX1 confers proliferative advantage to AML cells. (A) Overall survival of AML patients from TCGA clinical datasets (n 5 187).
Patients were divided into 3 groups according to their RUNX1 expressions (RUNX1 high: n 5 62; RUNX1 intermediate: n 5 63; RUNX1 low: n 5 62). (B) Efficacy of shRNAs
targeting RUNX1. MV4-11 cells were transduced with lentivirus encoding shRNA targeting Luciferase (sh_Luc.) or shRNAs against RUNX1 (sh_Rx1_moderate 1 or
sh_Rx1_profound 1) and incubated with 3 mM of doxycycline for 48 h, then total RNA was prepared and analyzed by RT-PCR. Values are normalized to that of control vector-
transduced cells (n 5 3). (C) Immunoblot showing the RUNX1 expressions in panel B. (D) Growth curves of MV4-11 cells transduced with control (sh_Luc.) or with RUNX1
shRNAs (sh_Rx1_moderate 1 or sh_Rx1_profound 1). Cells were cultured in the presence of 3 mM of doxycycline (n 5 3). (E) RUNX1 depletion-mediated change in the
number of cells with S 1 G2/M phase DNA content. MV4-11 cells transduced with control (sh_Luc.) or with RUNX1 shRNAs (sh_Rx1_moderate 1 or sh_Rx1_profound 1)
were cultured in the presence of 3 mM of doxycycline. Forty-eight hours after treatment, cells were harvested and subjected to flow cytometric analysis (n 5 3). (F) Frequency
of early apoptotic cell death induced by RUNX1 silencing. MV4-11 cells transduced with control (sh_Luc.) or with RUNX1 shRNAs (sh_Rx1_moderate 1 or sh_Rx1_profound 1)
were treated as in panel E, and the early apoptotic cells (annexin V1 DAPI2) were scored by flow cytometric analysis (n 5 3). Data are mean 6 SEM values. *P , .05; **P , .01,
by 2-tailed Student t test (except for panel A); ***P , .001, by log-rank (Mantel-Cox) test.
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Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed paraffin-
embedded tissue sections using antibodies directed against human
CD45 antigen (IR751, DAKO) for xenograft experiments. The
antigen–antibody complexes were visualized with Histofine Simple
Stain MAX PO (Nichirei Bioscience). The tissue section images
were captured using a BZ-X700 All-in-One Fluorescence Micro-
scope (Keyence, Japan).
Luciferase reporter assay
Putative promoter region of GSTA2 (21590 bp to 1100 bp of
transcription start site) was cloned from the genomic DNA of
MV4-11 cells using the following primers: F 59-CATAGTAAA-
ATGCCTATGACCAGATT-39 and R 59-ATGCTGTCACCTT-
TGTGGC-39; it was then subcloned into pGL4.20 (luc2/Puro)
vector (Promega). Both pGL4.20 GSTA2 promoter vector
and pRL-CMV control vector (TOYO B-Net Co., LTD.) were
cotransfected into HEK293T cells that are stably expressing
shRNAs of sh_RUNX1_moderate, sh_RUNX1_profound, and
sh_Luc., or expression vectors of RUNX1, RUNX2, and RUNX3.
Promoter activities were measured using PicaGene Dual Sea
Pansy Luminescence Kit (TOYO B-Net Co., Ltd.) and detected










   
   


















Top 2000 up-regulated genes
in sh_Rx1_moderate #1










































Top 2000 down-regulated genes
in sh_Rx1_profound #1










































































Figure 2. Upregulation of GSTA2 in RUNX1 moderately attenuated AML cells. (A) Venn diagram showing the common genes that are upregulated in the RUNX1
moderately inhibited MV4-11 cells (sh_Rx1_moderate_1) while tightly downregulated in the RUNX1 profoundly inhibited ones (sh_Rx1_profound_1 and 2). (B) List of 21 genes
extracted in panel A. Fold change of each gene was calculated by dividing the signal intensity of each gene in RUNX1 moderately inhibited MV4-11 cells by that in MV4-11
cells transduced with control (sh_Luc.). (C) GSTA2 expressions were determined in MV4-11 cells transduced with lentivirus encoding shRNA targeting Luciferase (sh_Luc.) or
shRNAs against RUNX1 (sh_Rx1_moderate 1 or sh_Rx1_profound 1). Cells were incubated with 3 mM of doxycycline for 48 h, then total RNA was prepared and analyzed by
RT-PCR. Values are normalized to those of control vector-transduced cells (n 5 3). (D) Immunoblot of GSTA2, RUNX1, and GAPDH in MV4-11 cells used in panel C.
(E) GSTA2 expressions were analyzed in the AML patients from TCGA clinical datasets as in Figure 1A (RUNX1 high: n 5 62; RUNX1 intermediate: n 5 63; RUNX1 low:
n 5 62). Data are mean 6 SEM values. *P , .05; **P , .01, by 2-tailed Student t test.
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Figure 3. GSTA2 confers proliferation of AML cells through promoting cell cycle advancements. (A) Immunoblot of GSTA2 and GAPDH in MV4-11 cells transduced
with lentivirus expressing GSTA2 or control. Cells were incubated with 3 mM of doxycycline for 48 h before being lysed for protein extraction. (B) Growth curves of MV4-11
cells transduced with control or GSTA2-expressing vector (GSTA2 O/E). Cells were cultured in the presence of 3 mM of doxycycline (n 5 3). (C) Additive GSTA2 expression-
mediated change in the number of cells with S 1 G2/M-phase DNA content. MV4-11 cells transduced with control or GSTA2-expressing vector (GSTA2 O/E) were cultured
in the presence of 3 mM of doxycycline. Forty-eight hours after treatment, cells were harvested and subjected to flow cytometric analysis (n 5 3). (D) Frequency of early
apoptotic cell death induced by additive GSTA2 expression. MV4-11 cells transduced with control or GSTA2-expressing vector (GSTA2 O/E) were treated as in panel C, and
the early apoptotic cells (annexin V1 DAPI2) were scored by flow cytometric analysis (n 5 3). (E) Immunoblot of GSTA2 and GAPDH in MV4-11 cells transduced with
lentivirus encoding shRNA targeting Luciferase (sh_Luc.) or shRNAs against GSTA2 (sh_GSTA2 1 or sh_GSTA2 2). Cells were incubated with 3 mM of doxycycline for 48 h.
(F) Growth curves of MV4-11 cells transduced with lentivirus encoding shRNA targeting Luciferase (sh_Luc.) or shRNAs against GSTA2 (sh_GSTA2 1 or sh_GSTA2 2) with
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ROS detection assay
Intracellular ROS accumulation was measured by using ROS-Glo
H2O2 Assay Kit (Promega), according to the manufacturer’s
instructions. ARVO X5 (Perkin Elmer) was used to read the
luminescence.
Cell cycle and apoptosis assay
For cell-cycle analysis, cells were fixed in fixation buffer and
permeabilized with permeabilization wash buffer (BioLegend),
followed by an incubation with PBS containing 3% heat-
inactivated FBS, 49,6-diamidino-2-phenylindole (DAPI), and 100
mg/mL of RNase A. Cells were then subjected to flow cytometric
analysis. For apoptosis assay, apoptotic cells were detected
by Annexin V Apoptosis Detection Kit APC (eBioscience Inc.). In
brief, approximately 2 3 105 cells of the indicated control and
experimental groups were washed in PBS, suspended in annexin-
binding buffer, and then mixed with 5 mL of annexin V. The reaction
mixtures were incubated for 30 min. After incubation, cells were
diluted, stained with DAPI, and processed for flow cytometric
analysis.
Analysis of gene expression microarray
MV4-11 cells were transduced with control shRNA (sh_Luc.) or
with shRNAs targeting RUNX1 and subsequently incubated with
3 mM of doxycycline. Twenty-four hours after incubation, total
RNA was prepared, and its quality was assessed by using Agilent
2100 Bioanalyzer (Agilent Technologies). Cyanine 3-labeled
cRNA was generated in the presence of T7 polymerase and
purified, and its concentration was measured by using Nanodrop
ND1000 (version 3.5.2; Thermo Scientific). The resultant cRNA
(825 ng) was fragmented and subsequently hybridized with
Human Gene 2.1 ST Array Strip (Affymetrix). The raw data
together with the associated sample information were analyzed
by GeneSpring GX (version 12.1.0; Agilent Technologies), and
our microarray data have been deposited in National Center for
Biotechnology Information’s Gene Expression Omnibus (GEO
Series accession no. GSE98748). Gene Set Enrichment Anal-
ysis was used to analyze the microarray data obtained in the
present study.12
Statistics
Statistical significance of differences between control and exper-
imental groups was assessed by a 2-tailed unpaired Student t test
and was declared if the P value was less than .05. Equality of
variances in 2 populations was calculated with an F test. The results
were represented as the average 6 standard error of the mean
(SEM) values obtained from 3 independent experiments. In trans-
plantation experiments, animals were randomly allocated to each
experimental group, and the treatments were given with blinding.
The overall survival of mice was shown in a Kaplan-Meier curve.
Survival between the indicated groups was compared using the
log-rank test.
Mice
Nonobese diabetic (NOD)/Shi severe combined immunodeficiency
(scid), interleukin (IL) 2RgKO (NOG) mice were purchased from the
Central Institute for Experimental Animals (Japan). Littermates were
used as controls in all experiments.
Xenograft mouse model
Xenograft mouse models of human cancer cell lines were developed
using NOG mice. For leukemia mouse models, 2.0 3 106 cells/body
of MV4-11 cells were intravenously injected. Peripheral blood was
then collected every week, and chimerism was checked by flow
cytometer using anti-human CD45 antibody (BD Biosciences).
Seven days after injection, mice were treated with ethacrynic acid
(10 to 25 mg/kg body weight, daily per oral [po] administrations)
or with the equivalent amount of dimethyl sulfoxide (DMSO). Mice
were also continuously given oral doxycycline through drinking
water 7 days after posttransplant (diluted in drinking water at
1 mg/mL 1 3% sucrose).
Study approval
All animal studies were properly conducted in accordance with the
Regulation on Animal Experimentation at Kyoto University, on the
basis of International Guiding Principles for Biomedical Research
Involving Animals. All procedures used in this study were approved
by Kyoto University Animal Experimentation Committee (permit no.
Med Kyo 14332).
Results
RUNX1 moderate inhibition confers proliferative
advantage to AML cells
To explore whether levels of RUNX1 expression influence the
prognosis of AML patients, we first examined them in de novo AML
patient cohort from The Cancer Genome Atlas (TCGA) clinical
dataset (n 5 187). As is shown in supplemental Figure 1, close
inspection of RUNX1 expressions in these patients revealed
3 distribution peaks. Because all of them followed normal distribution
pattern when divided according to their RUNX1 expressions
(RUNX1 high: n 5 62; RUNX1 intermediate: n 5 63; RUNX1
low: n5 62) and the basic background characteristics such as age,
sex, and cytogenetic risks of the patients allocated were similar
among these cohorts (supplemental Table 4), we compared the
overall survival periods among them to verify the significance of
RUNX1 expressions in the prognosis of AML patients. Intriguingly,
as shown in Figure 1A, we found that RUNX1 intermediately
expressing AML patients exhibited the worst clinical outcomes
(shortest overall survival periods) among these 3 cohorts. We also
found that AML patients with low RUNX1 expressions showed
Figure 3. (continued) or without simultaneous transduction of shRNA targeting RUNX1 (sh_Rx1_moderate). Cells were cultured in the presence of 3 mM of doxycycline
(n 5 3). (G) Additive GSTA2 knockdown-mediated change in the number of cells with S 1 G2/M-phase DNA content were determined in RUNX1 moderately attenuated
MV4-11 cells. MV4-11 cells were cultured in the presence of 3 mM of doxycycline as in panel F. Forty-eight hours after treatment, cells were harvested and subjected to flow
cytometric analysis (n 5 3). (H) Frequency of early apoptotic cell death induced by additive GSTA2 knockdown in RUNX1 moderately attenuated MV4-11 cells. MV4-11 cells
were cultured and treated as in panel G, and the early apoptotic cells (annexin V1 DAPI2) were scored by flow cytometric analysis (n 5 3). Data are mean 6 SEM values.
*P , .05, by 2-tailed Student t test. O/E, overexpression.
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favorable prognosis in relation to those with intermediate or high
RUNX1 expressions (Figure 1A). These facts prompted us to
hypothesize that moderately attenuated RUNX1 expression might
accelerate the propagation of AML cells and profoundly repressed
RUNX1 decelerate it. To address this issue, we prepared several
tetracycline-inducible short hairpin RNAs (shRNAs) that could
control the expressions of RUNX1 at various levels in AML cells
(MV4-11 and MOLM-13 cells). Interestingly, although AML cells
that were transduced with shRNAs that could profoundly down-
regulate RUNX1 expressions below 10% of their original expres-
sions at protein level (sh_Rx1_profound 1 and 2), deteriorated the
proliferation speed of AML cells, AML cells that were transduced
with shRNAs that could moderately downregulate RUNX1 expres-
sions to around 70% of their original expressions (sh_Rx1_
moderate 1 and 2) paradoxically doubled the growth rate of AML cells
in comparison with the control AML cells transduced with shRNA-
targeting luciferase gene (sh_Luc.) (Figure 1B-D). Both MV4-11
and MOLM-13 cell lines are derived from AML patients with MLL
gene rearrangements, and previous reports suggest close in-
teraction between RUNX1 and MLL.3,13 To further extend the
robustness of our findings in AML, we also prepared sh_Rx1_
profound-transduced or sh_Rx1_moderate-transduced AML cell
lines without MLL rearrangements such asOCI-AML2 andOCI-AML3



















































































































































































Figure 4. GSTA2-mediated intracellular ROS removal positively-affects the proliferation of AML cells. (A) Intracellular ROS content was measured by a luminometer
in MV4-11 cells transduced with control (sh_Luc.) or with RUNX1 shRNAs (sh_Rx1_moderate and sh_Rx1_profound) in the presence of 3 mM of doxycycline for 48 h.
Values are normalized to those of control vector-transduced cells (n 5 3). (B) Intracellular ROS content was measured in MV4-11 cells transduced with lentivirus encoding
shRNA targeting Luciferase (sh_Luc.) or shRNAs against GSTA2 (sh_GSTA2 1 or sh_GSTA2 2) with or without simultaneous transduction of shRNA-targeting RUNX1
(sh_Rx1_moderate) in the presence of 3 mM of doxycycline for 48 hours. Values are normalized to those of control vector-transduced cells (n 5 3). (C) Intracellular ROS
content was measured in MV4-11 cells treated with b-lapachone at 100 to 200 nM or DMSO for 24 h (n 5 3). (D) The number of cells with S 1 G2/M-phase DNA content
was determined in MV4-11 cells, as in panel C. Twenty-four hours after treatment, cells were harvested and subjected to flow cytometric analysis (n 5 3). (E) Intracellular ROS
amount was measured in MV4-11 cells transduced with lentivirus-expressing GSTA2 or control. Cells were incubated with 3 mM of doxycycline for 48 h, then harvested and
subjected to flow cytometric analysis (n 5 3). (F) Graphic showing the interaction of RUNX, GST, ROS, and their effect on the cell cycle progression in AML cells. RUNX
modulate the expression of GSTA2 in AML cells and subsequently reduce intracellular ROS accumulations, which in turn promote the cell cycle advancement and contribute
to the propagation of the disease. Data are mean 6 SEM values. *P , .05, by 2-tailed Student t test; **P , .01; ***P , .001. GSH, glutathione.
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lines were thoroughly consistent with those obtained in MV4-11 and
MOLM-13 cells, underscoring the importance of finely tuned RUNX1
expressions in the proliferation of AML cells in general (supplemental
Figure 2A-B). As is shown in Figure 1E-F and supplemental
Figure 3A-E, AML cells transduced with sh_Rx1_profound showed
cell-cycle arrest at G0/G1 phase and enhanced apoptotic cell death,
whereas AML cells transduced with sh_Rx1_moderate showed
advancement of cell-cycle progression and a reduced number of
apoptosis cells. To investigate the underlying molecular mechanisms
of this paradoxical enhancement of tumor cell proliferation in RUNX1
moderately inhibited cells, we compared and analyzed the global
gene expression patterns in MV4-11 cells transduced with sh_Luc.,
sh_Rx1_moderate, and sh_Rx1_profound. To obtain a list of genes
that are consistently upregulated in RUNX1 moderately inhibited
AML cells while simultaneously downregulated in RUNX1 profoundly
inhibited ones, we first extracted the top 2000 upregulated genes in
sh_Rx1_moderate-tranduced MV4-11 cells and top 2000 down-
regulated genes in sh_Rx1_profound-transduced MV4-11 cells in
relation to sh_Luc.-transduced control cells (Figure 2A). We then
picked up 21 genes commonly upregulated in the RUNX1moderately
inhibited AML cells while tightly downregulated in the RUNX1
profoundly inhibited AML cells (Figure 2B). Among these genes, we
focused on the top-ranked geneGSTA2, because emerging evidence
suggests oncogenic property ofGST family genes through intracellular
ROS scavenging and cell-cycle progression advancement.7-9 Indeed,
qRT-PCR and immunoblotting revealed elevation of GSTA2 expres-
sion in RUNX1 moderate-inhibition and suppression of it in RUNX1
profound-inhibition both at mRNA and protein levels (Figure 2C-D).
Besides, analysis of gene expression profiles in the previously
mentioned TCGA dataset elucidated that the AML cells derived from
RUNX1 intermediately expressing AML patients exhibited the highest
GSTA2 expressions. These facts collectively indicated the existence of
an underlying mechanism involving GSTA2 that confers a growth
advantage to AML cells with moderately inhibited RUNX1 expressions
(Figure 2E).
GSTA2 plays a key role in the accelerated
proliferation of RUNX1 moderately inhibited
AML cells
To further elucidate the possible involvement of GSTA2 in this
paradoxically accelerated proliferation rate in RUNX1 moderately
inhibited AML cells, we examined the effect of additive expression
of GSTA2 in AML cells. As is shown in Figure 3A-D, GSTA2-
overexpressed MV4-11 cells showed increased proliferation rate,
enhanced advancement of cell-cycle progression, and suppressed
the frequency of apoptotic cells to the extent observed in RUNX1
moderately inhibited MV4-11 cells. Moreover, additive knockdown
of GSTA2 in sh_Rx1_moderate-tranduced MV4-11 cells exhibited







































































































































































Figure 5. Moderate inhibition of RUNX1 paradoxically upregulates total RUNX expression. (A) Expressions of RUNX1, RUNX2, RUNX3, and total RUNX
(Pan_RUNX) were determined in MV4-11 cells transduced with control (sh_Luc.) or with RUNX1 shRNAs (sh_Rx1_moderate and sh_Rx1_profound) in the presence of 3 mM
of doxycycline for 24 h. Values are normalized to those of control vector-transduced cells (n 5 3). (B) Schematic illustrations show proximal promoter region (22000 bp
to 1500 bp of transcriptional start site) of GSTA2. (C) ChIP analysis in MV4-11 cells using anti-RUNX1, anti-RUNX2, or anti-RUNX3 antibodies, an isotope-matched control
IgG and anti-histone H3 antibody. ChIP products were amplified by PCR to determine abundance of the indicated amplicons. R1 and R2 correspond to RUNX consensus-
binding sequences in the GSTA2 promoter, as is described in panel B. PRL30 was used as a negative control. (D) Luciferase reporter assay of GSTA2 promoter.
HEK293T cells were transduced with the indicated lentivirus vectors as well as with luciferase reporter plasmids and then incubated with 3 mM of doxycycline. Forty-eight
hours after treatment, relative luciferase activity was determined (n 5 3). Data are mean 6 SEM values. *P , .05, by 2-tailed Student t test; **P , .01; ***P , .001.
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control levels (Figure 3E-G) as well as reverted the sh_Rx1_moderate-
derived downregulation of apoptosis (Figure 3H). Moderate inhibition
of RUNX1-mediated growth advantage was consistently canceled by
additional GSTA2 knockdown in other AML cell lines as well (sup-
plemental Figure 4A-C). These findings elucidated the importance of
GSTA2 expressions in this paradoxically accelerated proliferation
speed of RUNX1 moderately inhibited AML cells. We next tried to
clarify the underlying molecular mechanisms of how GSTA2 confers
growth advantage to AML cells.
GSTA2 overexpression confers proliferative
advantage to AML cells through enhancing
intracellular ROS catabolization
Because GSTA2 catabolizes and scavenges free radicals such as
hydrogen peroxide (H2O2) and decreased intracellular free radicals
have been shown to accelerate the cell-cycle advancement,8,10 we
first measured the amount of intracellular ROS in RUNX1-inhibited
AML cells. As is shown in Figure 4A, intracellular ROS accumulation
was decreased in sh_Rx1_moderate-transduced MV4-11 cells and
increased in AML cells transduced with sh_Rx1_profound. Besides,
additive delivery of sh_RNAs targetingGSTA2 to sh_Rx1_moderate-
tranduced MV4-11 cells restored the intracellular ROS accumulation
to the control level (Figure 4B). Indeed, direct ROS induction with
b-lapachone, a validated topoisomerase I inhibitor, significantly de-
celerated the cell-cycle progression in these AML cells (Figure 4C-D).
Furthermore, as is shown in Figures 3B and 4E, forced expression
of GSTA2 to MV4-11 cells conferred proliferative advantage through
suppressing the intracellular ROS content, underscoring the idea that
growth advantage conferred by moderate RUNX1 inhibition could be
attributed to the sequential upregulation ofGSTA2 and downregulation
of intracellular ROS accumulation in AML cells (Figure 4F).
Significance of total amount of RUNX expressions in
GSTA2 upregulation
We next investigated the molecular mechanisms underlying this
completely opposite directional regulation of GSTA2 expression
between RUNX1 profoundly and moderately attenuated AML cells.





























































































































   
   

























































Figure 6. RUNX family members transactivate GSTA2 expression. (A) Expressions of RUNX1, RUNX2, RUNX3, and total RUNX (Pan_RUNX) were determined in MV4-11
cells transduced with control or with expressing vectors of RUNX1, RUNX2, and RUNX3 in the presence of 3 mM of doxycycline for 24 h. Values are normalized to those of
control vector-transduced cells (n 5 3). (B) Expressions of GSTA2 were determined in MV4-11 cells as in panel A. Values are normalized to those of control vector-transduced
cells (n 5 3). (C) Expressions of RUNX1, RUNX2, RUNX3, GSTA2, and GAPDH were determined in MV4-11 cells transduced with control or with expressing vectors of
RUNX1, RUNX2, and RUNX3 in the presence of 3 mM of doxycycline for 48 h (n 5 3). (D) Luciferase reporter assay of GSTA2 promoter. HEK293T cells were transduced
with the indicated lentivirus vectors as well as with luciferase reporter plasmids and then incubated with 3 mM of doxycycline. Forty-eight hours after treatment, relative
luciferase activity was determined (n 5 3). (E) Growth curves of MV4-11 cells as in panel A. Cells were cultured in the presence of 3 mM of doxycycline (n 5 3). Data are
mean 6 SEM values. *P , .05, by 2-tailed Student t test; **P , .01.
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RUNX family members such as RUNX2 and RUNX3 upon RUNX1
silencing, because RUNX family members have redundant biological
functions in leukemogenesis6 and this mutual compensation among
RUNX family members could possibly take part in the fine-tuning of
GSTA2 expressions. Interestingly, the equivalent level of compensa-
tory upregulation of RUNX2 and RUNX3 expressions were observed
in sh_Rx1_moderate-transduced and sh_Rx1_profound-transduced
AML cells. These elevations created an absolute gap in the total
amount of RUNX family (RUNX1 1 RUNX2 1 RUNX3) expressions
in between sh_Rx1_moderate-transduced and sh_Rx1_profound-
transduced AML cells, which was confirmed by RT-qPCR with
primers amplifying the specific sequence common to all RUNX family
members (Figure 5A). ChIP assay in the proximal promoter region of
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Figure 7. Effective control of AML through targeting RUNX-GST-ROS axis in vivo. (A) Schematic diagram showing the xenotransplantation AML model in NOG mice.
Mice were transplanted with 2 3 106 cells/body of MV4-11 cells stably transduced with indicated lentivirus via tail veins (day 1). At day 7, po doxycycline administration
through drinking water was started. In experiments using ethacrynic acid, mice were treated either by daily po ethacrynic acid or control until they showed any physical sign of
AML development. (B) Overall survival of NOG mice transplanted with MV4-11 cells properly transduced with control (sh_Luc.) or with RUNX1 shRNAs (sh_Rx1_moderate
1 and sh_Rx1_profound 1) (n 5 8). P value by log-rank (Mantel-Cox) test. (C) Representative microscopic images of bone marrow prepared from AML xenograft mice as in
panel B (21 d posttransplantation). Results obtained from hematoxylin and eosin (HE) staining and immunohistochemical staining with anti-human CD45 antibody were shown
(original magnification 34 and 320 (insets); scale bars, 100 mm). (D) Intracellular ROS content was measured in MV4-11 cells treated with ethacrynic acid at 25 to 50 mM or
DMSO for 72 h (n 5 3). (E) The number of cells with S 1 G2/M-phase DNA content was determined in MV4-11 cells as in panel D. Seventy-two hours after treatment, cells
were harvested and subjected to flow cytometric analysis (n 5 3). (F) Overall survival of NOG mice transplanted with MV4-11 cells properly transduced with sh_Rx1_moderate
1. Mice were treated either by daily po ethacrynic acid (10 to 25 mg/kg body weight) or by control solvents (n 5 5). P value by log-rank (Mantel-Cox) test. *P , .05; **P , .01.
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members with this genomic area (Figure 5B-C). Luciferase reporter
assay using the GSTA2 promoter showed elevation of reporter
signals in sh_Rx1_moderate-transduced cells and suppression of
them in sh_Rx1_profound-transduced cells (Figure 5D). Consistent
with these findings, forced upregulation of the total amount of RUNX
expression by additive RUNX1, RUNX2, or RUNX3 expressions
in AML cells (Figure 6A) resulted in transactivation of GSTA2
expression (Figure 6B-D) and augmented cell proliferations in AML
cells (Figure 6E). In summary, these data indicate that each RUNX
family member enhances transactivation of GSTA2 expression in
AML cells; paradoxically upregulated total RUNX expressions by
moderate inhibition of RUNX1 results in increased expression of
GSTA2; and upregulatedGSTA2 transcripts subsequently confer a
growth advantage to RUNX1 moderately inhibited AML cells
through suppressing intracellular ROS accumulation.
Targeting RUNX-GST-ROS axis in vivo
We finally examined our hypothesis in vivo using immunodeficient
NOG mice xenotransplanted with human AML cells (Figure 7A).
In concrete terms, we transplanted sh_Luc-, sh_Rx1_moderate-
tranduced or sh_Rx1_profound-tranduced MV4-11 cells to NOG
mice and induced in vivo shRNA expressions through po adminis-
tration of doxycycline. As we have expected, mice transplanted with
RUNX1 moderately inhibited AML cells showed shorter overall
survival periods in comparison with the control mice, whereas mice
transplanted with RUNX1 profoundly inhibited AML cells exhibited
significant extension of overall survival periods in relation to the
control mice (Figure 7B-C). To achieve effective in vivo attenuation of
GSTA2 in these mice, we used ethacrynic acid in our experiments, a
widely recognized potent GST inhibitor.14 Treating AML cells with
ethacrynic acid in vitro indeed resulted in cell-cycle arrest at the
G0/G1 phase and intracellular ROS accumulations as are seen in
RUNX1-profoundly inhibited AML cells (Figure 7D-E). We thus
challenged NOG mice transplanted with sh_Rx1_moderate-
transduced MV4-11 cells with this drug and observed their overall
survival periods. As is shown in Figure 7F, AML mice treated with
ethacrynic acid (10 mg/kg body weight or 25 mg/kg body weight,
daily po administrations) exhibited significantly prolonged survival
periods in comparison with vehicle-treated control mice. These data
suggest that targeting GSTA2 could be a novel therapeutic strategy
against poorest prognostic AML cases with intermediate RUNX1
expressions.
Discussion
RUNX1 transcription factor plays a pivotal role in cancer develop-
ment and maintenance as well as in the homeostasis of various
organs.15,16 Although RUNX1 has been shown to exhibit both
oncogenic and oncosuppressive properties context-dependently
in various cancers, little has been known about the molecular
mechanisms underlying this curious bidirectional function of
RUNX1.3,5,15,17,18 In addition, although mutations in RUNX1 have
been reported to demarcate poorer-prognostic cohorts in AML
patients,19-21 the level of RUNX1 expression itself has not been
directly linked to the outcomes of AML patients. Recently, we have
reported that RUNX cluster regulation is a promising therapeutic
strategy against various types of cancers, including AML.6 Although
our previous work validated the antitumor potential of RUNX1-
inhibiton strategy, the precise mechanisms of how RUNX1 engages
in tumorigenesis remain elusive. While assessing the significance of
RUNX1 expressions in the prognosis of de novo AML patients, we
have coincidentally found that the RUNX1-intermediately-expressing
cohort exhibit the worst outcomes among them. Therefore we
focused on this “moderate” expression of RUNX1 in AML and
presumed that analyzing the biology ofRUNX1moderately expressing
AML cells might unveil the hidden mechanisms of RUNX-mediated
tumorigenesis. Of note, the property of transcription factors acting in
some contexts as activators but in others as repressors has been
reported.22-27 Among them, F. Rosenbauer et al have produced
interesting data showing that reducing ETS family transcription factor
Pu.1 expression to 20% of wild-type levels results in an aggressive
form of AML development in mice, whereas complete loss of its
expression did not.24 Their finding in the balanced expression of Pu.1
in leukemogenesis is similar in nature to our findings in RUNX1 and
strongly suggest the importance of finely tuned expressions of vital
transcription factors in leukemogenesis.
In this report, we further addressed the underlying mechanism in
this paradoxical enhancement of leukemogenesis in RUNX1
moderately attenuated AML cells and attained pieces of evidence
showing that moderate inhibition of RUNX1 results in the elevation
of total RUNX family expressions, which transactivates GSTA2
expression and removes intracellular ROS from AML cells. If
intracellular ROS accumulation is controlled at low range, an
increase in ROS is actually associated with abnormal cancer cell
growth.8,10 If the increase of ROS reaches a certain threshold
level that is incompatible with cellular survival, however, in-
tracellular ROSs exert a cytotoxic effect, leading to arrest of the
cell-cycle progression and induction on apoptosis in malignant
cells, and limits cancer progression.8,10,28 Thus, intracellular ROS
inducers constitute one of the most intensively studied antitumor
strategies, and some of these drugs are clinically available with
promising outcomes.28 In respect to the role of RUNX1 in ROS
regulation, V. Giambra et al reported that the NOTCH1–RUNX3–
RUNX1–PKC-u transcriptional circuit plays a pivotal role in the
regulation of intracellular ROS and maintenance of T-cell acute
lymphoblastic leukemia (T-ALL) cells, but to our limited knowledge,
none have previously investigated the role of RUNX1 in the
regulation of ROS in the context of AML cells. Taking the
considerable difference in the pathogenesis of AML and ALL into
account, our findings of the RUNX-GST-ROS axis are highly
meaningful in the precise understanding of the role of RUNX1 in
intracellular ROS control in AML cells.
To attenuate the function of GSTA2 in our study, we adopted the
classical GST inhibitor ethacrynic acid, because this drug is clinically
available as a diuretic drug with few side effects. In our AML mice
model, we discovered a favorable impact of this drug on the prognosis
of AML mice through modulating RUNX-GST-ROS axis in vivo. Our
promising results and the efficacy of this implementable antileukemia
strategy should be examined further in upcoming clinical trials. Taken
together, these findings indicate that moderately attenuated RUNX1
expressions paradoxically enhance leukemogenesis in AML cells
through intracellular environmental change via GSTA2, which could
be a novel therapeutic target in antileukemia strategy.
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